每經AI快訊，苑東生物晚間公(gong)(gong)告，公(gong)(gong)司全資(zi)子公(gong)(gong)司成都碩德(de)(de)藥(yao)(yao)業有限公(gong)(gong)司（簡稱(cheng)“碩德(de)(de)藥(yao)(yao)業”）于近日收到美(mei)(mei)國(guo)(guo)食(shi)品(pin)藥(yao)(yao)品(pin)監(jian)督管理(li)局（簡稱(cheng)“美(mei)(mei)國(guo)(guo)FDA”）的通知，碩德(de)(de)藥(yao)(yao)業向(xiang)美(mei)(mei)國(guo)(guo)FDA申報的鹽(yan)(yan)酸尼卡(ka)地平(ping)注射(she)液的簡化(hua)新藥(yao)(yao)申請(qing)（ANDA，即美(mei)(mei)國(guo)(guo)仿制藥(yao)(yao)申請(qing)）獲(huo)得正(zheng)式批準(zhun)。鹽(yan)(yan)酸尼卡(ka)地平(ping)注射(she)液的主要成份為鹽(yan)(yan)酸尼卡(ka)地平(ping)，適應癥為用于無法口服給藥(yao)(yao)時的高(gao)血壓短(duan)期治療。